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Prophylactic and therapeutic  
effects of twice-daily famciclovir  
administration on infectious  
upper respiratory disease  
in shelter-housed cats
Ann E Cooper1 , Sara M Thomasy2*, Tracy L Drazenovich2,  
Philip H Kass3, Sanskruti S Potnis2, Christian M Leutenegger4 
and David J Maggs2
Abstract
Objectives In humans with herpetic disease, early or pre-emptive famciclovir therapy reduces disease duration 
and severity. This prospective, masked, placebo-controlled study tested therapeutic and prophylactic effects of two 
famciclovir doses given to cats for 7 days following shelter entry.
Methods Cats were assigned to prophylactic or therapeutic study arms based on clinical evidence of herpetic 
disease at study entry. Cats in the therapeutic arm received no treatment (n = 19), placebo (lactose; n = 18) or 
famciclovir at ~30 (n = 21) or ~90 mg/kg (n = 20) PO q12h for 7 days. Cats in the prophylactic arm received no 
treatment (n = 25) or famciclovir at ~30 (n = 28) or ~90 mg/kg (n = 27) PO q12h for 7 days. Disease scores, 
body weight, conjunctival feline herpesvirus 1 (FHV-1) shedding, and adoption rates were recorded on days 1 
(admission), 8 (end of therapy) and 15 (1 week after cessation of therapy).
Results No significant differences in clinical scores were observed among groups in the prophylactic or therapeutic 
arms at any of the three time points. However, within the therapeutic arm, viral shedding on day 8 was significantly 
higher in cats receiving no treatment than in those receiving ~30 or ~90 mg/kg famciclovir, and this effect persisted 
1 week after famciclovir was stopped (day 15) only in cats receiving ~30 mg/kg, although this approached 
significance in cats receiving ~90 mg/kg. No significant differences in adoption rates were detected among groups 
in either arm throughout the study.
Conclusions and relevance Although we did not demonstrate a statistically or clinically significant effect of famciclovir 
administration upon clinical signs of infectious upper respiratory disease or adoption, when it was administered at 
~30 or ~90 mg/kg q12h for 1 week famciclovir reduced conjunctival FHV-1 shedding. This suggests a potential role 
in interrupting the infectious cycle within a shelter population; however, cost in time and resources, and stress and 
pathogen transmission induced by oral administration should be considered.
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Introduction
Infectious upper respiratory disease (IURD) is a com-
mon and important management problem in multi-cat 
environments, with feline herpesvirus type 1 (FHV-1) 
believed to be one of the major causes of severe and 
recurrent disease.1–5 In shelters, physiologic stresses 
leading to viral reactivation in latently infected cats are 
common as a result of high turnover, crowding and vari-
able vaccination history and immunocompetency; thus, 
FHV-1 shedding and herpetic disease are extremely 
prevalent in shelter-housed cats.2,3 Currently, the lack of 
effective methods to control IURD within shelters has 
resulted in clinical IURD being one of the major reasons 
for euthanasia or difficulty adopting cats from shelters, 
and remains a notable management and welfare concern 
in multi-cat environments worldwide.2,3
Although administration of antiviral drugs to humans 
with herpes simplex virus or in animal models of her-
petic disease reduces establishment of latency,6 reactiva-
tion frequency7 and viral shedding,8 to our knowledge, 
antiviral drugs have not been assessed in this way in 
FHV-1-infected cats. Until recently, systemically admin-
istered antiviral medications were considered too toxic 
or insufficiently effective for use in cats.9,10 However, 
data regarding the safety and efficacy in cats of famciclo-
vir – an antiviral prodrug of penciclovir – are extremely 
promising, and its use in shelter-housed cats warrants 
investigation. We, and others, have shown that penciclo-
vir – the active metabolite of famciclovir – is highly effec-
tive against FHV-1 in vitro.11–14 We have also extensively 
assessed the pharmacokinetics (PK), pharmacodynam-
ics, safety and efficacy of famciclovir in normal, as well 
as experimentally and naturally infected cats. Although 
famciclovir PK are complex and non-linear,15–17 the drug 
is highly effective in cats with experimentally induced or 
spontaneous herpetic disease,15,18,19 with improved sys-
temic, ophthalmic, clinicopathologic, virologic and his-
tologic outcomes all noted without adverse effects.
Preliminary investigations into the utility of famciclo-
vir as a prophylactic agent in a shelter setting have thus 
far proven unsuccessful. In a 2015 study, famciclovir, 
when administered as a single dose of 125 or 500 mg (16–
52 or 92–227 mg/kg, respectively) to cats upon shelter 
entry, did not reduce shedding of FHV-1 DNA or clinical 
disease scores compared with placebo-treated cats at the 
1 week time point assessed. Furthermore, sneezing scores 
increased and body weight (BW) decreased compared 
with study entry in cats that received 500 mg famciclovir 
or placebo.20 However, this study did not explore the 
effects of oral famciclovir administered over a prolonged 
dosing period and cats were not stratified based on clini-
cal scores at the time of study entry. If a fiscally and logis-
tically viable method of administering famciclovir to cats 
in shelters is as effective at limiting viral shedding and 
clinical signs of disease as it is in humans, this drug 
would have extraordinary potential to reduce disease 
prevalence and severity, and minimize viral shedding, 
thereby revolutionizing management, improving animal 
welfare, reducing euthanasia rates and promoting adop-
tion within shelters worldwide.
Therefore, the present study was designed to investi-
gate the clinical and virologic effects of prophylactic and 
therapeutic administration of two doses of famciclovir 
administered to cats for 1 week beginning immediately 
upon shelter admission. We hypothesized that, relative to 
placebo, q12h oral administration of famciclovir for a 
period of 1 week at ~90 mg/kg, but not at ~30 mg/kg, 
would reduce incidence and severity (prophylactic arm) 
and prevalence, duration and severity (therapeutic arm) 
of feline IURD, thereby reducing euthanasia rates and 
increasing adoption rates. Furthermore, we hypothesized 
that these effects would persist beyond the 1 week admin-
istration period and that incidence of adverse events 
would not differ between famciclovir doses.
Materials and methods
This study was conducted between March and November 
2016 in a county animal shelter in Northern California. 
Cats were considered for enrollment in this study within 
48 h of being put up for adoption. Prior to this, cats were 
held for the legally mandated period of 72 h, during 
which they were spayed or castrated if not already, and 
underwent behavioral testing. All participating cats were 
individually housed and fed in the shelter’s adoption 
facility and remained eligible for adoption throughout 
the study. For entry into the study, cats were required to 
test negative for serum feline leukemia virus (FeLV) anti-
gens and feline immunodeficiency virus (FIV) antibodies 
(SNAP Combo FeLV Ag-FIV Antibody test; IDEXX), have 
a body condition score (BCS) ⩾3/9,21 be ⩾1 kg BW and 
be ⩾3 months of age (estimated based upon dental exam-
ination). For cats meeting these inclusion criteria, clinical 
signs of IURD were graded by masked observers accord-
ing to a published semi-quantitative scoring system.22 
The total clinical disease score was defined as the sum of 
all ocular (conjunctivitis, blepharospasm and ocular dis-
charge) plus all non-ocular (sneezing and nasal dis-
charge) scores. The minimum total clinical disease score 
possible was 0 and the maximum was 24.
Based upon clinical disease score, cats meeting all eli-
gibility criteria were assigned to one of two study arms 
– one designed to test the prophylactic effects and the 
other to test the therapeutic effects of famciclovir given 
at one of two doses to cats for 1 week beginning at shel-
ter entry (Figure 1). Cats without evidence of IURD (ie, 
clinical disease score = 0) were assigned to the prophy-
lactic arm of the study, whereas cats with evidence of 
IURD (ie, clinical disease score ⩾1) were assigned to the 
therapeutic arm. Within each arm, cats were stratified 
based upon sex, estimated age group and clinical disease 
546 Journal of Feline Medicine and Surgery 21(6)
score, and then randomized into treatment groups such 
that all groups in both arms had approximately equiva-
lent distribution of sex (male or female without consid-
eration of neuter status) and estimated age group (<12 
months or ⩾12 months). Group assignment was per-
formed by a single individual who was not involved 
with clinical assessment of cats. Within the prophylactic 
arm cats received either no treatment or ~30 mg/kg or 
~90 mg/kg oral famciclovir q12h. 
Within the therapeutic arm, cats were assigned to the 
same three treatment groups plus a group that received 
placebo (lactose PO q12h). In both arms, famciclovir was 
administered using commercially available tablets 
(Apotex) that were crushed, weighed and placed into 
gelatin capsules to provide either ~30 or ~90 mg/kg 
depending on group assignment and based upon twice-
weekly recordings of each cat’s BW. Cat BW was rounded 
up to the nearest 0.5 kg and dose calculated as described 
in Table 1.
For the placebo group, lactose was similarly placed in 
gelatin capsules at an approximate volume to a 30 mg/ kg 
dose of famciclovir. Capsules containing lactose or fam-
ciclovir were administered using a commercially availa-
ble pill administration device and followed by 1 ml tap 
water delivered orally via a dosing syringe. Each cat 
received twice daily famciclovir or placebo for 1 week 
but remained in the study for a further 1 week (total of 2 
weeks) of observation unless adopted.
Cats in all treatment groups of both study arms were 
managed according to the shelter’s usual protocols in all 
respects other than drug/placebo administration. All cats 
underwent general health assessment by shelter caretak-
ers at least once daily as was routine in this shelter. All 
changes were noted as potential adverse events. In addi-
tion, BW and BCS was recorded twice weekly and cats 
that lost >15% of their entry BW were removed from the 
study. Clinical evidence of IURD was graded once daily 
by trained observers using the same scale used at study 
entry. Cats that entered with signs of IURD or became 
affected by IURD during the study were treated accord-
ing to this shelter’s IURD protocol, which included the 
systemic administration of doxycycline (or, in one cat 
only, azithromycin) and/or the topical administration of 
oxytetracycline–polymyxin ophthalmic ointment. These 
cats remained in the study and continued to receive fam-
ciclovir or placebo according to their group assignment 
in addition to the medical care dictated by the shelter 
protocol. Cats known to receive any other antibiotics 
were excluded from all data analysis. 
On days 1, 8 and 15 (ie, at study entry, at cessation of 
famciclovir/placebo administration, and 7 days follow-
ing drug cessation), cats in all treatment groups received 
1 drop of 0.5% proparacaine (Akorn) in each eye, and a 
dry polyester swab (Fisher Scientific) was vigorously 
rolled in the ventral conjunctival fornix of both eyes. 
Swabs were immediately placed in sterile 1.5 ml 
Eppendorf tubes and stored on ice for 1–3 h, and then at 
4°C until quantification of FHV-1 DNA by means of a 
qPCR assay (IDEXX Laboratories), according to pub-
lished protocols.23
For the duration of the study, personnel were assigned 
either an evaluator or observer role. Those personnel 
assigning clinical scores remained masked to treatment 
group and study arm and entirely separate from those 
administering treatments. All data collected prior to 
removal of cats from the study were included in the 
analyses. The χ2 test of homogeneity was used to detect 
differences among groups with respect to sex regardless 
of neuter status, and neuter status regardless of sex. 
Kruskal–Wallis one-way ANOVA was used to detect dif-
ferences in age among treatment groups. Time to adop-
tion among treatment groups and between study arms 
was compared using a log-rank test; unadopted individ-
uals were censored after 16 days. The presence of FHV-1 
Figure 1 Study design by which cats were selected for entry 
and randomly assigned to one of seven treatment groups 
within the prophylactic or therapeutic study arm of a clinical 
trial assessing the efficacy of famciclovir administered at one 
of two doses for 1 week following shelter entry. FeLV = feline 
leukemia virus; FIV = feline immunodeficiency virus; BCS = 
body condition score; IURD = infectious upper respiratory 
disease; CS = clinical score
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DNA was compared among treatment groups within 
particular days and study arms using logistic regression. 
The effects of treatment group, time and their interaction 
on clinical disease scores was evaluated using mixed-
effects linear regression, with the individual cat treated 
as a random effect. For all analyses, a P value <0.05 was 
considered significant. Personnel making decisions 
regarding euthanasia, adoption and movement of cats 
within the hospital were all unaware to which treatment 
group cats were assigned. 
The study was approved by the Institutional Animal 
Care and Use Committee of the University of California–
Davis and designed in accordance with the ARVO state-
ment for the ethical use of animals in ophthalmic research.
Results
Demographics
A total of 163 cats met all enrollment criteria; however, 
data from five cats were removed before analysis. Data 
were removed from one cat in the ~30 mg/kg group of the 
prophylactic arm because of a suspected recording error 
in which pounds were used instead of kilograms for body 
weight. Data from the remaining four cats were removed 
because these cats received oral antibiotics other than 
doxycycline or azithromycin. Of these, two cats were in 
the untreated group, one was in the ~30 mg/kg group in 
the prophylactic arm and one was in the ~90 mg/kg 
group in the therapeutic arm. 
Thus, final data were analyzed for 158 cats; 146 
domestic and 12 purebred (one Bombay, two Himalayan, 
one Maine Coon, five Siamese and three Snowshoe) cats 
divided approximately equally among the seven treat-
ment groups (Table 2). None of the cats were considered 
markedly brachycephalic. There were 91 females and 67 
males with a median age of 25 months (range 3–168 
months). Of these, 80 cats were already neutered upon 
intake to the shelter, 77 were spayed or castrated by shel-
ter veterinary staff prior to study entry and one was an 
intact female. At admission, no significant differences 
were detected among groups with respect to sex, regard-
less of neuter status (P = 0.176), neuter status regardless 
of sex (P = 0.147), or age (P = 0.860). Owing to the small 
number of purebred cats, breed distribution was not sta-
tistically analyzed; however, the purebred cats were 
approximately equally distributed across 6/7 treatment 
groups; the ~90 mg/kg group within the therapeutic 
arm had no purebred cats (see Table 2).
Clinical signs
Although on day 0 all cats in the prophylactic arm had a 
clinical disease score of 0 (as defined by entry criteria) and 
all cats in the therapeutic arm had a clinical disease score 
>0, these scores had sometimes changed by day 1, which 
was considered the baseline for the study. Despite this, 
median (range) clinical disease scores on day 1 did not sig-
nificantly differ among cats entered into the three treat-
ment groups of the prophylactic arm or the four treatment 
groups of the therapeutic arm (see Table 2). Furthermore, 
no significant differences in clinical disease scores were 
observed among any groups within the prophylactic arm 
(Figure 2a) or therapeutic arm (Figure 2b) at the end of the 
period of famciclovir/placebo administration (day 8) or 1 
week after cessation of therapy (day 15). No cats in either 
study arm had a clinical disease score >12 at baseline (day 
1) or at study termination (day 15), and, across all seven 
treatment groups of both arms, only six cats achieved a 
clinical score >12 at any point during the 2 week study. All 
six were in the therapeutic arm and, of these, four (two 
from placebo group, one that received ~30 mg/kg famci-
clovir and one that received ~90 mg/kg famciclovir) had a 
clinical score >12 at the conclusion of the 1 week treatment 
period (day 8); however this had returned to <12 by day 
Table 1 Based upon twice-weekly assessment of body weight, cats received a famciclovir dose that approximated (but 
was never less than) 30 or 90 mg/kg q12h for 7 days following shelter entry
Cat body weight (kg) ~30 mg/kg famciclovir treatment group ~90 mg/kg famciclovir treatment group
 Dose administered 
(mg)
Dose administered 
(mg/kg)
Dose administered 
(mg)
Dose administered 
(mg/kg)
1.0–1.49 45 30–45 135 90–135
1.5–1.99 60 30–40 180 90–120
2.0–2.49 75 30–38 225 90–113
2.5–2.99 90 30–36 270 90–108
3.0–3.49 105 30–35 315 90–105
3.5–3.99 120 30–34 360 90–103
4.0–4.49 135 30–34 405 90–101
4.5–4.99 150 30–33 450 90–101
5–5.49 165 30–33 495 90–99
5.5–6.0 180 30–33 540 90–98
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15. Considering the remaining two cats, one was in the ~90 
mg/kg famciclovir group and had a clinical score >12 on 
days 10 and 16, while the last was in the placebo group 
and had a clinical score >12 on days 3, 5, 7 and 9–13.
Herpetic DNA
Within the prophylactic arm of the study, the proportion 
of cats in which FHV-1 DNA was detected in the con-
junctival fornices was generally low (0–13%), and did 
not significantly differ at any time point statistical analy-
sis was possible (ie, at baseline [day 1] among any of the 
three treatment groups, or at the conclusion of the 1 week 
treatment period [day 8] between the no-treatment and 
~90 mg/kg famciclovir groups; Figure 3a). Comparisons 
among other groups in the prophylactic arm on day 8 
and among any treatment groups on day 15 were not 
possible owing to the paucity of cats shedding FHV-1 in 
these groups at these times.
Within the therapeutic arm of the study, herpetic 
DNA was detected in the conjunctival fornices of a large 
proportion (45–47%) of cats in the untreated group on all 
3 days. This permitted statistical comparison of the 
presence of conjunctival herpetic DNA data between 
untreated cats and those in the three treatment groups at 
all three time points (Figure 3b). At baseline (day 1), 
FHV-1 DNA was detected in the conjunctival fornices of 
a significantly greater proportion of cats in the untreated 
group than in the placebo (P = 0.0214; odds ratio [OR] 
0.081, 95% confidence interval [CI] 0.0016–0.77) or ~30 
mg/kg (P = 0.0103; OR 0.068, 95% CI 0.0013–0.63) but 
not the ~90 mg/kg (P = 0.2470; OR 0.36, 95% CI 0.069–
1.70) groups. For placebo-treated cats, this difference 
was no longer evident on day 8 (P = 0.2451; OR 0.30, 
95% CI 0.038–1.81) but had returned by day 15 (P = 
0.0174; OR 0.078, 95% CI 0–0.67). Relative to the untreated 
group, significantly fewer cats receiving ~30 mg/kg 
famciclovir shed virus after 1 week of therapy (P = 
0.0176; OR 0.073, 95% CI 0.0014–0.72), and this effect per-
sisted until day 15 (P = 0.0094; OR 0.064, 95% CI 0–0.54). 
Whereas, significantly fewer cats receiving ~90 mg/kg 
famciclovir than those that were untreated shed virus 
after 1 week of therapy (P = 0.0384; OR 0.14, 95% CI 
0.011–0.92), and this effect approached significance on 
day 15 (P = 0.0531; OR 0.089, 95% CI 0.0016–1.03).
Considering data from all cats regardless of study 
arm and treatment group, FHV-1 DNA was detected on 
46 occasions in 32 cats. Of these, there were 25 for which 
PCR data were available at all three time points. Ten of 
these were positive at baseline but then ceased shedding 
at the end of the 1 week treatment period (day 8) and 
remained negative 1 week after cessation of treatment 
(day 15). Of these two were untreated, and eight received 
famciclovir at either ~30 (n = 4) or ~90 (n = 4) mg/kg. 
By contrast, four cats were positive at all three time 
points throughout the study; three were in the untreated 
group, whereas only one received famciclovir (~90 mg/
kg). Finally, three cats were negative at baseline but shed 
on both days 8 and 15; one cat was untreated and the 
other received ~90 mg/kg famciclovir.
Adoption data
A significant difference in time to adoption was not 
detected among treatment groups in both arms (P = 0.8802 
or among both arms in all treatment groups [P = 0.4022]; 
Table 3).
Discussion
This study revealed that famciclovir did not prevent or 
reduce clinical signs of IURD when administered orally at 
~30 or ~90 mg/kg for 1 week following  shelter entry to cats 
Table 2 Baseline demographic and clinical data for 158 cats entered into a clinical trial assessing the efficacy  
of famciclovir administered at one of two doses for 1 week following shelter entry
Prophylactic arm Therapeutic arm
 Untreated
(n = 25)
~30 mg/kg 
famciclovir 
q12h
(n = 28)
~90 mg/kg 
famciclovir 
q12h
(n = 27)
Untreated
(n = 19)
Placebo 
q12h
(n = 18)
~30 mg/kg 
famciclovir 
q12h
(n = 21)
~90 mg/kg 
famciclovir 
q12h
(n = 20)
Age (months)
 Median
 Range 
25
7–168
24.5
6–120
24
3–72
26
6–120
30.5
4–156
36
8–120
21
4–168
Breed 23 D, 2 P 25 D, 3 P 24 D, 3 P 17 D, 2 P 17 D, 1 P 20 D, 1 P 20 D, 0 P
Sex 13 F, 12 M 14 F, 14 M 20 F, 7 M 7 F, 12 M 13 F, 5 M 12 F, 9 M 12 F, 8 M
Clinical disease 
score
 Median
 Range
0
0–2
0
0–2
0
0–7
2
0–8
1
0–10
1
0–8
4
0–9
Cats were randomly assigned to 1/7 treatment groups within the prophylactic or therapeutic study arms. Age and sex distributions were not 
significantly different among groups. Breed distribution was not statistically analyzed
D = domestic; F = female; M = male; P = purebred
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with or without signs of IURD. However, when adminis-
tered at ~30 or ~90 mg/kg to cats with signs of IURD, fam-
ciclovir was associated with reduced viral shedding at the 
end of the 1 week treatment period. This effect did not per-
sist 1 week after the cessation of therapy for cats receiving 
the higher dose but did in cats receiving ~30 mg/kg q12h. 
No significant differences in adoption rates were detected 
among groups in either arm throughout the study.
Findings in the present study that famciclovir did not 
prevent or reduce clinical signs of IURD at the two doses 
tested when administered for 1 week following shelter 
Figure 2 Clinical disease scores for 158 cats entered into a 
clinical trial assessing the efficacy of famciclovir administered 
at one of two doses for 1 week following shelter entry. (a) Cats 
without clinical signs of infectious upper respiratory disease 
(IURD) at study entry were assigned to the prophylactic 
study arm and stratified to receive famciclovir at ~30 mg/
kg (n = 28; yellow) or ~90 mg/kg (n = 27; red) PO q12h or 
were untreated (n = 25; blue). (b) Cats with signs of IURD 
at study entry were assigned to the therapeutic study arm 
and received famciclovir at ~30 mg/kg (n = 21; yellow) or 
~90 mg/kg (n = 20; red) PO q12h, placebo PO q12h (n = 
18; green) or were untreated (n = 19; blue). No significant 
differences in clinical disease scores were observed among 
any groups within the (a) prophylactic or (b) therapeutic arms 
at the end of the period of famciclovir/placebo administration 
(day 8) or 1 week after cessation of therapy (day 15)
Figure 3 Proportions of cats in which feline herpesvirus type 
1 (FHV-1) DNA was detected in the conjunctival fornix of 
either eye on days 1, 8 or 15 of a clinical trial assessing the 
efficacy of famciclovir administered at one of two doses for 
1 week following shelter entry. (a) Cats without clinical signs 
of infectious upper respiratory disease (IURD) at study entry 
were assigned to the prophylactic study arm and stratified to 
receive famciclovir at ~30 mg/kg (n = 28; yellow) or ~90 mg/
kg (n = 27; red) PO q12h or were untreated (n = 25; blue). 
Within the prophylactic arm of the study, the proportion of cats 
in which FHV-1 DNA was detected in the conjunctival fornices 
did not significantly differ at any time point statistical analysis 
was possible. (b) Cats with signs of IURD at study entry were 
assigned to the therapeutic study arm and received famciclovir 
at ~30 mg/kg (n = 21; yellow) or ~90 mg/kg (n = 20; red) PO 
q12h, placebo PO q12h (n = 18; green) or were untreated (n 
= 19; blue). At baseline (day 1), FHV-1 DNA was detected in 
the conjunctival fornices of a significantly greater proportion 
of cats in the untreated group than in the placebo or ~30 mg/
kg groups but not the ~90 mg/kg groups. For placebo-treated 
cats, this difference was no longer evident on day 8 but had 
returned by day 15. For cats receiving ~30 mg/kg famciclovir, 
significantly fewer shed virus after 1 week of therapy and this 
effect persisted until day 15. For cats receiving ~90 mg/kg 
famciclovir, significantly fewer shed virus after 1 week of therapy 
and this effect approached significance on day 15
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entry are in accordance with those from a previous study,20 
in which a single oral dose of 125 or 500 mg famciclovir 
(16–52 or 92–227 mg/kg, respectively) was administered 
to cats upon shelter entry. In that study,20 clinical disease 
scores obtained 1 week after medication administration 
did not significantly differ between those cats receiving 
the antiviral drug and those receiving the placebo.
Given famciclovir’s potent antiviral effect in cats 
experimentally infected with FHV-1,15 and in client-
owned cats with presumed herpetic disease,18 it is inter-
esting to consider why an effect was not seen in the 
present or previous study conducted in shelter environ-
ments.20 First, the low incidence of IURD at the shelter 
where the present study was performed and the mild 
clinical disease noted may have affected this outcome. 
Specifically, the mild clinical signs seen are likely to have 
made subtle changes in clinical course more difficult to 
detect. No cats in the present study had a clinical disease 
score >12 at baseline (day 0) or study termination (day 
15). Interestingly, 4/6 cats in the therapeutic arm (two 
from placebo group, one that received ~30 mg/kg, fam-
ciclovir and one that received ~90 mg/kg famciclovir) 
had a clinical score >12 at the conclusion of the 1 week 
treatment period (day 8), which was no longer >12 at 1 
week later (day 15), suggesting that the act of pilling 
may have transiently worsened clinical disease.
Second, the relatively short course of famciclovir 
administration may have been insufficient to detect a 
clinical effect. The study was originally designed to 
include a 2 week course of treatment followed by a 2 
week period of observation. However, during the pilot 
phase, the time course was shortened owing to difficulty 
getting cats through to study completion due to factors 
such as transfer and adoption. Third, it is possible that 
IURD signs scored in cats of the present study were due 
to non-infectious causes, or pathogens other than FHV-1 
not sensitive to famciclovir. Certainly, the other major 
respiratory pathogens of cats – Chlamydia felis, Mycoplasma 
species and feline calicivirus – would not be expected to 
be sensitive to an acyclic nucleoside, such as penciclovir. 
Furthermore, coinfection with FHV-1 and other respira-
tory pathogens may have made clinical improvement 
due to antiviral treatment more difficult to detect.
Although famciclovir did not prevent or reduce clini-
cal signs of IURD in the shelter population studied here, 
some significant differences in viral DNA detection at 
the conjunctival surface were detected among groups. 
For example, administration of famciclovir at ~30 or ~90 
mg/kg to cats with signs of IURD (ie, in the therapeutic 
arm of the study) was associated with reduced viral 
shedding at the end of the 1 week treatment period. This 
effect persisted 1 week after cessation of therapy in the 
~30 mg/kg group, and the difference approached sig-
nificance in the ~90 mg/kg group suggesting that a 
larger data set may have revealed significance.
Meanwhile, an interesting trend was detected among 
cats with clinical disease at study entry and entered into 
the untreated or placebo group. Although FHV-1 DNA 
was detected more commonly in cats in the untreated 
group than the placebo group at all time points, it 
remained relatively constant at each time point tested. 
By comparison, 7 days of pilling of placebo-treated cats 
was associated with a notable increase in FHV-1 DNA 
detection rate, which subsided to about (or slightly less 
than) baseline 7 days after pilling had ceased. This raises 
the possibility that stress and/or fomite transmission 
among cats being pilled twice daily may induce herpetic 
shedding. This is in accordance with findings of a previ-
ous study,20 in which cats receiving a single dose of fam-
ciclovir or placebo at shelter entry had increased rates of 
FHV-1 shedding vs untreated controls. If true, this sug-
gests that the decision to administer famciclovir (or any 
other oral medications) in shelters and perhaps else-
where may not be a benign act. Rather, it may even have 
negative consequences for the individual receiving the 
medication or FHV-1-naïve in-contact cats.
Because relatively few cats across all treatment groups 
were shedding FHV-1, as detected by FHV-1 PCR 
Table 3 Adoption data for the 158 cats entered into a clinical trial assessing the efficacy of famciclovir administered at 
one of two doses for 1 week following shelter entry
Prophylactic arm Therapeutic arm
 Untreated
(n = 25)
~30 mg/kg 
famciclovir 
q12h
(n = 28)
~90 mg/kg 
famciclovir 
q12h
(n = 27)
Untreated
(n = 19)
Placebo 
q12h
(n = 18)
~30 mg/kg 
famciclovir 
q12h
(n = 21)
~90 mg/kg 
famciclovir 
q12h
(n = 20)
Time to adoption 
(days)
 Median
 Range
5
1–12
3
0–12
8
5–13
7.5
2–8
14
3–15
8
3–10
10.5
2–15
Number adopted 7 8 5 4 4 3 4
Time to adoption was recorded for cats in all treatment groups of both study arms. Unadopted individuals were censored after 16 days
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performed on conjunctival swabs, inferences drawn 
from these data must be interpreted with caution. This is 
particularly true for cats for which PCR data were avail-
able at all three time points. However, within this group, 
viral shedding trends suggested that cats receiving no 
treatment were more likely to shed FHV-1 throughout 
the study than those receiving famciclovir at ~90 mg/kg. 
Furthermore, cats shedding FHV-1 at baseline were less 
likely to continue shedding virus at subsequent time 
points if they received famciclovir at ~30 or ~90 mg/kg 
than those that received no treatment.
Philosophically, it is interesting to consider whether 
many of the differences in this study that were not statis-
tically significant may have become significant had the 
number of cats assessed in each group been larger. While 
an a priori power analysis is helpful in such settings, it 
would have been based upon pure conjecture here given 
the absolute novelty of the study design. However, to 
explore the possibility of the effect of sample size, it is 
interesting to assess the likely clinical significance of 
such changes had we been able to demonstrate signifi-
cance. Taking, as an example, the non-significant differ-
ences in clinical scores – the greatest difference between 
averages of any two groups was 3 (and more typically 2) 
on a scale of 0–24. Such differences would likely be of 
minimal if any clinical significance. For example, a dif-
ference in a clinical score of just 2 could be accounted for 
by minor serous discharge from one nostril and one eye. 
Likewise, the proportion of cats shedding DNA varied 
among groups by 0–13%. Against studies that show 
shedding rates of up to 50% in normal cats,24,25 this seems 
likely to be a relatively minor clinical effect.
Conclusions
We were unable to demonstrate a statistically or clinically 
significant effect upon clinical signs of IURD or adoption 
rates when famciclovir was administered to cats at ~30 or 
~90 mg/kg for 1 week following shelter entry. However, 
when administered at ~30 or ~90 mg/kg, famciclovir was 
associated with reduced herpes viral shedding at the con-
junctival surface at the end of the 1 week treatment 
period, and this effect persisted for a further week of 
treatment in the ~30 mg/kg group. Although this sug-
gests that famciclovir therapy may have the ability to 
interrupt the infectious cycle within a shelter population 
via reduction of FHV-1 shedding, this concept warrants 
further consideration, especially as it relates to the cost in 
time and resources, as well as the stress and potential 
spread of FHV-1 and other pathogens associated with fre-
quent oral drug administration in a shelter setting.
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